Back to everyone

Sally Dewhurst

Principal, Life Sciences

Sally Dewhurst

Sally joined Oxford Science Enterprises in February 2021, bringing over 8 years of oncology-focused research experience from world-leading academic institutions.

She works on uncovering new opportunities across the Life Sciences and supports the creation of new biotech businesses as well as the management of the existing portfolio.

Sally was previously an Anderson Cancer Center Post-Doctoral Fellow at the Rockefeller University in New York where her research focused on genetic instability at the very earliest stages of cancer development. Prior to this, she completed a PhD at the Francis Crick Institute in London where she uncovered an important role for polypoid cells in driving cancer evolution.

Academic research that Sally has contributed to has been published in leading journals including Nature Genetics, Nature Communications and Cancer Discovery.

Sally has also studied corporate finance at NYU, and consulted for The Solution Lab.

Sally sits on the board of

  • Alethiomics
  • Grey Wolf Therapeutics

Sally is an observer on the board of

  • DJS Antibodies
  • Kesmalea

Meet everyone in the

Life Sciences Team

Chris Ashton
Chris AshtonAdvisor, Life Sciences
Claire Brown
Claire BrownPartner, Life Sciences
Craig Fox
Craig FoxOperating Partner, Life Sciences
Jon Hepple
Jon HeppleAdvisor, Life Sciences
Katharina Ramshorn
Katharina RamshornAnalyst
Katya Smirnyagina
Katya SmirnyaginaSenior Partner, Life Sciences
Sanne de Jongh
Sanne de JonghPartner, Life Sciences
Selina Greuel
Selina GreuelAssociate
Siegfried Thun-Hohenstein
Siegfried Thun-HohensteinAnalyst